Introduction
Gastric cancer, death, tumors, malignancy
GASTRIC CANCER, GASTRIC CANCER, TUMORS
Gastric cancer is the third leading cause of cancer‐related death and the fifth most common malignancy diagnosed worldwide [Based on the results of a previous randomized controlled trial, the sixth edition of the Japanese Gastric Cancer Treatment Guidelines defines a regimen combining a platinum-based agent and a fluorouracil-based agent, including S-1 plus oxaliplatin (SOX), capecitabine plus oxaliplatin (CapeOX), and FOLFOX, as an acceptable first-line chemotherapy regimen for patients with epidermal growth factor receptor 2 (HER2)-negative AGC [Capecitabine is an oral fluoropyrimidine rationally designed to preferentially generate 5-fluorouracil (5-FU) in tumors and might be a safer option than S-1 in older patients [Therefore, this prospective multicenter phase II study (UMIN000022450/jRCTs051180126) aims to examine the efficacy and safety of CapeOX in Japanese older patients with AGC.